Arrowhead Reports Phase 3 Plozasiran Data Reducing Pancreatitis
Pasadena, Calif. – August 30, 2026 Arrowhead Pharmaceuticals presented detailed Phase 3 SHASTA-3 and SHASTA-4 data showing that plozasiran...
triglycerides
Advertisement
CRISPR Therapeutics Reports Durable CTX310 Lipid Lowering
Zug, Switzerland & Boston, Mass. – August 28, 2026 CRISPR Therapeutics presented new Phase 1a durability data for CTX310,...
Ionis and AstraZeneca Showcase Cardiovascular Pipeline Progress with New Data at ESC Congress 2026
CARLSBAD, California, August 20, 2026 Ionis Pharmaceuticals, Inc. announced that new clinical data supporting its severe hypertriglyceridemia (sHTG) treatment...
Arrowhead Expands REDEMPLO Access for FCS in Germany
PASADENA, Calif., August 17, 2026 Arrowhead Pharmaceuticals, Inc. announced that people living with familial chylomicronaemia syndrome (FCS) in Germany...
Arrowhead Pharmaceuticals Reports Positive Phase 3 Plozasiran Results
PASADENA, Calif., July 22, 2026 Arrowhead Pharmaceuticals announced positive topline results from its pivotal Phase 3 SHASTA-3 and SHASTA-4...
Advertisements
Ionis Wins FDA Approval for TRYNGOLZA in Severe Hypertriglyceridemia
CARLSBAD, Calif., June 24, 2026 Ionis Pharmaceuticals announced that the U.S. Food and Drug Administration (FDA) has approved TRYNGOLZA®...
Cambrian Bio Reports Positive Phase 1b ATX-304 Data
NEW YORK, N.Y. | June 18, 2026 Cambrian Bio has presented positive Phase 1b clinical data for ATX-304, the...
Arrowhead Gains CHMP Nod for REDEMPLO in Rare Disease
Pasadena, California | April 24, 2026 Arrowhead Pharmaceuticals has achieved a major regulatory milestone as the Committee for Medicinal...
Advertisement
